source
- Entrada's Duchenne drug shows disappointing early data, shares tumbleEntrada disclosed initial results from a low‑dose version of its exon‑44 skipping therapy for Duchenne muscular dystrophy. The data, collected from six patients, failed to meet the company’s expect…
- Amgen invests $300 million in Puerto Rico biologics plant as Novartis plans to close German oral drug factoryAmgen announced an additional $300 million investment in Puerto Rico to expand its biologics manufacturing capacity in Juncos, building on earlier commitments. The funding will be used to upgrade…